Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / G.I. and Other Associated Cancers Research Group / Discovered galectin-3 ligand as a serum biomarker of colon cancer

Discovered galectin-3 ligand as a serum biomarker of colon cancer

Discovered galectin-3 ligand as a serum biomarker of colon cancer with sensitivity 72% and specificity 80% based on blinded validation in standard reference set.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take on a date and location to be determined.